cancer immunotherapy Archives -

For the first time, patients in England with triple-negative breast cancer (TNBC) will be able to access immunotherapy

NICE backs use of MSD’s KEYTRUDA for triple-negative breast cancer

https://pharmaphorum.com/news/nice-backs-use-of-msds-keytruda-for-triple-negative-breast-cancer/

Oncology/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

Cancer vaccines: providing the edge in oncology

Ben Hargreaves cancer immunotherapy, cancer vaccines, Vaccitech 0 Comment

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may

Cancer vaccines: providing the edge in oncology

https://pharmaphorum.com/oncology/cancer-vaccines-providing-the-edge-in-oncology/

Oncology/ Views & Analysis/ Views and analysis/ Webinars/ Webinars in home page/ Webinars On demand

Oncology treatment decisions aren’t just based on clinical data

mike.hammerton@pharmaphorum.com Brand marketing, cancer immunotherapy, Cerner Enviza, oncology research 0 Comment

Once widely acknowledged as so special that only scientists and clinical specialists need to apply, oncology has become

Oncology treatment decisions aren’t just based on clinical data

https://pharmaphorum.com/webinars/oncology-treatment-decisions-arent-just-based-on-clinical-data/

Can in vivo imaging deliver the full potential of immunotherapy

News/ News/ Oncology

German biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapy

Catherine Longworth cancer, cancer immunotherapy, CatylYm, financing, Oncology 0 Comment

CatalYm has closed a €50 million ($59m) series B financing round to fund clinical studies of its immunotherapy

German biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapy

https://pharmaphorum.com/news/german-biotech-catalym-raises-e50-million-for-gdf-15-inhibitor-immunotherapy/

News/ News/ Oncology/ Top stories

Pfizer picks up rights to CStone’s cancer immunotherapy sugemalimab in China

Richard Staines cancer immunotherapy, CStone, Pfizer 0 Comment

Pfizer has paid $200 million to buy 9.9% of Hong Kong-listed cancer biotech CStone, beginning a strategic collaboration

Pfizer picks up rights to CStone’s cancer immunotherapy sugemalimab in China

https://pharmaphorum.com/news/pfizer-picks-up-rights-to-cstones-cancer-immunotherapy-sugemalimab-in-china/

Oncology/ Views & Analysis/ Views and analysis/ White Papers/ Whitepapers

Preparing for the next decade of innovation in immuno-oncology

mike.smith@pharmaphorum.com Advanced Clinical, cancer, cancer immunotherapy, immuno-oncology, Oncology, personalised medicine 0 Comment

Immuno-oncology has seen some striking clinical advances in the 10 years since the approval of the first therapeutic

Preparing for the next decade of innovation in immuno-oncology

https://pharmaphorum.com/oncology/immuno-oncology-clinicial-trial-market-access/

News/ News/ R&D

Gilead poaches oncology expert Quigley from BMS

Richard Staines Bristol-Myers Squibb, cancer, cancer immunotherapy, CAR T, Gilead, Kite, R&D 0 Comment

Gilead has poached an oncology research leader from Bristol-Myers Squibb, appointing Michael Quigley as senior vice president of

Gilead poaches oncology expert Quigley from BMS

https://pharmaphorum.com/news/gilead-poaches-oncology-expert-quigley-from-bms/

News/ News/ Oncology

AZ joins with Seres to research role of gut microbiome in cancer

Richard Staines AstraZeneca, cancer, cancer immunotherapy, gastrointestinal, Seres Therapeutics 0 Comment

AstraZeneca has announced an immuno-oncology collaboration with US biotech Seres Therapeutics, which will focus on increasing understanding of

AZ joins with Seres to research role of gut microbiome in cancer

https://pharmaphorum.com/news/az-joins-with-seres-to-research-role-of-gut-microbiome-in-cancer/

News/ News/ Oncology/ Top stories

Keytruda could get patient-friendly 6 week dosing schedule in EU

Richard Staines Bristol-Myers Squibb, cancer, cancer immunotherapy, Merck & Co 0 Comment

US-based Merck & Co is putting further pressure on its arch-rival Bristol-Myers Squibb with a potential new six-week

Keytruda could get patient-friendly 6 week dosing schedule in EU

https://pharmaphorum.com/news/keytruda-could-get-patient-friendly-6-week-dosing-schedule-in-eu/

Trending

cancer immunotherapy

Login